Applied dna receives approximately $3.6 million in net proceeds from warrant exercise

Stony brook, n.y.--(business wire)---- $apdn #lineardna--applied dna sciences, inc. (nasdaq: apdn) (the “company”), a leader in polymerase chain reaction (“pcr”)-based technologies, announced that it has received approximately $3.6 million in net proceeds following an exercise of series b warrants by an institutional investor in the company. the series b warrants exercised were issued in connection with a public offering that closed on august 8, 2022. each series b warrant entitles its owner to purchase one share o
APDN Ratings Summary
APDN Quant Ranking